

Financial news for SNSS dated on 2020-06-10: 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for SNSS dated on 2020-05-08: H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Lowers Price Target to \$0.5

Financial news for SNSS dated on 2020-05-08: Sunesis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Financial news for SNSS dated on 2020-05-07: Sunesis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Financial news for SNSS dated on 2020-05-07: Sunesis Pharmaceuticals Q1 EPS \$(0.050) Beats \$(0.070) Estimate, Sales \$120.000K Miss \$190.000K Estimate

Financial news for SNSS dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for SNSS dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for SNSS dated on 2020-05-01: 20 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for SNSS dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for SNSS dated on 2020-03-13: Sunesis Pharmaceuticals trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak, the healthcare sector has been extremely volatile.

Financial news for SNSS dated on 2020-03-11: Benzinga's Top Upgrades, Downgrades For March 11, 2020

Financial news for SNSS dated on 2020-03-11: Sunesis Pharmaceuticals shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered the price target from \$3 to \$1 per share.

Financial news for SNSS dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for SNSS dated on 2020-03-11: H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Raises Price Target to \$1

Financial news for SNSS dated on 2020-03-11: Wells Fargo Downgrades Sunesis Pharmaceuticals to Equal-Weight, Lowers Price Target to \$1

Financial news for SNSS dated on 2020-03-10: Sunesis Pharmaceuticals Q4 EPS \$(0.05) Beats \$(0.07) Estimate

Financial news for SNSS dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for SNSS dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for SNSS dated on 2020-02-19: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for SNSS dated on 2020-01-28: 43 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for SNSS dated on 2020-01-21: 20 Biotechnology Stocks Moving In Tuesday's After-Market Session

Financial news for SNSS dated on 2020-01-21: 29 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for SNSS dated on 2020-01-07: Sunesis Pharma 8-K Shows Co. Granted Second 180-Calendar Day Compliance Period, Or Until Jul. 6, 2020, To Demonstrate Compliance

Financial news for SNSS dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for SNSS dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for SNSS dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for SNSS dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for SNSS dated on 2019-12-06: Sunesis Pharma 8-K Shows Co. Entered Deal To Terminate Certain License Deal With Sumitomo For Patents Related To Vosaroxin, Related Compounds; Co. Will Make 1-Time Payment Of \$150K

Financial news for SNSS dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for SNSS dated on 2019-12-05: Sunesis Pharma Reports Data From Ongoing Phase 1b/2 Trial Of Vecabrutinib In Patients With CLL, Other B-Cell Malignancies

Financial news for SNSS dated on 2019-12-05: Stocks That Hit 52-Week Lows On Thursday

Financial news for SNSS dated on 2019-11-12: Sunesis Pharmaceuticals Q3 EPS \$(0.06) Beats \$(0.08) Estimate

Financial news for SNSS dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for SNSS dated on 2019-10-29: 28 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for SNSS dated on 2019-10-16: Sunesis Pharmaceuticals Announces Presentation Of SNS-510 Pre-Clinical Data At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Financial news for SNSS dated on 2019-08-09: Sunesis Pharmaceuticals Option Alert: Oct 18 \$1 Calls Sweep (4) near the Ask: 879 @ \$0.25 vs 2818 OI; Ref=\$0.8399

Financial news for SNSS dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for SNSS dated on 2019-08-07: Sunesis Pharmaceuticals Q2 EPS \$(0.09) Beats \$(0.10) Estimate

Financial news for SNSS dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for SNSS dated on 2019-07-12: 55 Biggest Movers From Yesterday

Financial news for SNSS dated on 2019-07-11: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for SNSS dated on 2019-07-11: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for SNSS dated on 2019-07-11: Sunesis Pharmaceuticals shares are trading lower after the company announced a public offering of common and preferred stock.

Financial news for SNSS dated on 2019-07-11: The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

Financial news for SNSS dated on 2019-07-11: 7 Stocks To Watch For July 11, 2019

Financial news for SNSS dated on 2019-07-11: Sunesis Prices 33.33M Share Common Stock Offering @\$0.60/Share

Financial news for SNSS dated on 2019-07-10: Sunesis Reports Common And Preferred Stock Offering; Size Not Disclosed

Financial news for SNSS dated on 2019-07-10: Sunesis Pharmaceuticals shares are trading lower after the company announced a public offering of common and preferred stock.

Financial news for SNSS dated on 2019-07-09: 52 Biggest Movers From Yesterday

Financial news for SNSS dated on 2019-07-08: A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019

Financial news for SNSS dated on 2019-07-08: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for SNSS dated on 2019-07-08: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, July 8, 2019

Financial news for SNSS dated on 2019-07-08: Sunesis Pharmaceuticals shares are trading higher after the company announced it has completed the safety evaluation period for the 200 mg cohort of the Phase 1b/2 trial of vecabrutinib; to date, the safety profile has had no drug-related adverse events.

Financial news for SNSS dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for SNSS dated on 2019-06-12: Sunesis Pharmaceuticals Option Alert: Jun 21 \$1 Calls Sweep (31) near the Ask: 1429 @ \$0.151 vs 114 OI; Earnings 8/6 After Close [est] Ref=\$0.663

Financial news for SNSS dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for SNSS dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for SNSS dated on 2019-05-08: Sunesis Pharmaceuticals Q1 EPS \$(0.1) Beats \$(0.17) Estimate

Financial news for SNSS dated on 2019-03-07: Sunesis Pharmaceuticals Q4 EPS \$(0.16) Beats \$(0.21) Estimate

Financial news for SNSS dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for SNSS dated on 2019-01-22: 52 Biggest Movers From Friday

Financial news for SNSS dated on 2019-01-18: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for SNSS dated on 2019-01-18: Sunesis Pharmaceuticals shares are trading lower after the company announced a 23 million share offering at \$0.50 per share.

Financial news for SNSS dated on 2019-01-18: 40 Stocks Moving In Friday's Pre-Market Session

Financial news for SNSS dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for SNSS dated on 2019-01-18: 10 Stocks To Watch For January 18, 2019

Financial news for SNSS dated on 2019-01-18: Sunesis Pharmaceuticals Prices 23M Share Offering @\$0.50/Share

Financial news for SNSS dated on 2019-01-17: Sunesis Pharma Announces Proposed Common Stock and Preferred Stock Offer, Size Not Disclosed

Financial news for SNSS dated on 2019-01-11: Penny stock Sunesis Pharma shares up 27% on 3x normal daily volume despite a lack of news. Shares broke above the \$0.60 resistance level at Friday morning's open.

Financial news for SNSS dated on 2019-01-02: Sunesis Pharmaceuticals Announces Advancement Into 100mg Cohort Of Phase 1b/2 Trial Of Vecabrutinib In Patients With CLL And Other B-Cell Malignancies

Financial news for SNSS dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for SNSS dated on 2018-12-20: H.C. Wainwright Initiates Coverage On Sunesis Pharmaceuticals with Neutral Rating, Announces \$0.50 Price Target

Financial news for SNSS dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for SNSS dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for SNSS dated on 2018-12-11: The Daily Biotech Pulse: Management

Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for SNSS dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for SNSS dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for SNSS dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for SNSS dated on 2018-12-02: Sunesis Pharmaceuticals Announces Presentation of Encouraging Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH 2018

Financial news for SNSS dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for SNSS dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for SNSS dated on 2018-11-28: The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Financial news for SNSS dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for SNSS dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for SNSS dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for SNSS dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for SNSS dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for SNSS dated on 2018-11-05: Sunesis Pharmaceuticals, Inc. Q3 EPS \$(0.18) Beats \$(0.22) Estimate

Financial news for SNSS dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for SNSS dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for SNSS dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for SNSS dated on 2018-08-07: Sunesis Pharmaceuticals Q2 EPS \$(0.20) Beats \$(0.24) Estimate

Financial news for SNSS dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for SNSS dated on 2018-06-25: UPDATE: Sunesis Pharma Announces Aspire Capital Made Initial Investment Via Purchase of \$500K Worth Of Common Shares at \$2.19/Share, Has Committed To Purchasing An Additional \$15M

Financial news for SNSS dated on 2018-06-25: Sunesis Pharma Enters Purchase Agreement With Aspire Capital For \$15.5M Common Stock

Financial news for SNSS dated on 2018-06-08: 45 Biggest Movers From Yesterday

Financial news for SNSS dated on 2018-05-08: Sunesis Pharmaceuticals Q1 EPS \$(0.21) Beats \$(0.27) Estimate, Sales \$237K Beat \$200K Estimate

Financial news for SNSS dated on 2018-03-15: 42 Biggest Movers From Yesterday

Financial news for SNSS dated on 2018-03-13: Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference, Cancellation Due to Travel Changes Caused by Inclement Weather

Financial news for SNSS dated on 2018-03-13: Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference Due to Travel Changes Caused by Weather

Financial news for SNSS dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for SNSS dated on 2018-03-09: Mid-Afternoon Market Update: Crude Oil Up Over 3%; PDL BioPharma Shares Spike Higher

Financial news for SNSS dated on 2018-03-09: Sunesis Pharma Down 41% On Extended Timeline For Vecabrutinib Dose-Escalation Study

Financial news for SNSS dated on 2018-03-09: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for SNSS dated on 2018-03-09: Mid-Day Market Update: Dow Rises Over 250 Points; AutoWeb Shares Plunge

Financial news for SNSS dated on 2018-03-09: Mid-Morning Market Update: Markets Open Higher; Finisar Earnings Miss Views

Financial news for SNSS dated on 2018-03-08: Sunesis Pharma Reports Q4 EPS \$(0.21) vs \$(0.29) Est.

Financial news for SNSS dated on 2018-03-08: Sunesis Pharmaceuticals Q4 Earnings Preview

Financial news for SNSS dated on 2018-03-05: Sunesis Pharma 13G Filing From Boxer Capital Shows Raised Stake From 1.325M Shares At End Of Last Qtr. To 2.125M Shares, Or 6.2% Stake

Financial news for SNSS dated on 2018-02-01: 46 Biggest Movers From Yesterday

Financial news for SNSS dated on 2018-01-05: 36 Biggest Movers From Yesterday

Financial news for SNSS dated on 2018-01-04: Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher

Financial news for SNSS dated on 2018-01-04: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for SNSS dated on 2017-12-12: 42 Biggest Movers From Yesterday

Financial news for SNSS dated on 2017-12-11: Sunesis Pharmaceuticals Spikes to High of \$3.57 on Volume

Financial news for SNSS dated on 2017-12-11: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for SNSS dated on 2017-12-11: Benzinga's Top Upgrades, Downgrades For December 11, 2017

Financial news for SNSS dated on 2017-12-11: Wells Fargo Upgrades Sunesis Pharmaceuticals to Outperform

Financial news for SNSS dated on 2017-12-05: Benzinga's Top Upgrades, Downgrades For December 5, 2017

Financial news for SNSS dated on 2017-12-05: Wells Fargo Downgrades Sunesis Pharmaceuticals to Market Perform

Financial news for SNSS dated on 2017-12-05: Sunesis Pharmaceuticals Says it Will Provide a Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017

Financial news for SNSS dated on 2017-12-04: Sunesis Pharmaceuticals CEO Daniel Swisher CEO Resigns Effective End of 2017, Will Remain As Strategic Advisor, Dayton Misfeldt Named Interim CEI Effective Jan. 2018

Financial news for SNSS dated on 2017-11-30: Sunesis Pharma Names William Quinn CFO

Financial news for SNSS dated on 2017-11-22: 40 Biggest Movers From Yesterday

Financial news for SNSS dated on 2017-11-21: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SNSS dated on 2017-11-21: Benzinga's Top Upgrades, Downgrades For November 21, 2017

Financial news for SNSS dated on 2017-11-21: Oppenheimer Initiates Coverage On Sunesis Pharmaceuticals with Outperform Rating

Financial news for SNSS dated on 2017-11-20: STAT's Adam Feurstein Tweets: 'There's

an analyst named Hartaj Singh at Oppenheimer who just initiated on \$CLSN and \$SNSS w/ outperform ratings, \$9 and \$7 PTs, respectively. Poor guy. FHL.'

Financial news for SNSS dated on 2017-11-07: Sunesis Pharmaceuticals 10%+ Owner UBS Oncology Impact Fund L.P. Buys 81,500 @ Avg Price: \$2.77 -Form 4

Financial news for SNSS dated on 2017-11-02: Sunesis Pharma Reports Q3 EPS \$(0.43) vs. \$(0.37) Est., No Sales

Financial news for SNSS dated on 2017-11-01: 46 Biggest Movers From Yesterday

Financial news for SNSS dated on 2017-10-31: Sunesis Pharmaceuticals Director Dayton Misfeldt Buys 600,000 @ Avg Price: \$1.33 -Form4

Financial news for SNSS dated on 2017-10-24: Sunesis Pharma Reports Offering Of Common Stock, Series D Convertible Preferred Shares, Warrants, No Size Disclosed

Financial news for SNSS dated on 2017-07-27: Sunesis Pharmaceuticals Reports Q2 EPS \$(0.41) vs \$(0.59) Est.

Financial news for SNSS dated on 2017-07-18: Sunesis Pharma Reports First Patient Dosed In Phase 1b/2 Study Evaluating SNS-062 In Adults With Chronic Lymphocytic Leukemia, Other B-Cell Malignancies

Financial news for SNSS dated on 2017-07-05: 13G Filing From Balyasny Asset Mgmt On Sunesis Pharma Shows 9.32% Stake

Financial news for SNSS dated on 2017-06-23: UPDATE: Sunesis Says 32 Out Of 35 Patients Completed Greater Than Or Equal To 1 Cycle, Were Evaluable For Response

Financial news for SNSS dated on 2017-06-23: Sunesis Pharma Offers Updated Results From Phase 1/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS: Showed Encouraging Response Rates

Financial news for SNSS dated on 2017-05-08: Sunesis Pharma Q1 EPS \$(0.47) vs \$(0.17) Est, Sales \$669K vs \$630K Est

Financial news for SNSS dated on 2017-05-02: 18 Biggest Mid-Day Losers For Tuesday

Financial news for SNSS dated on 2017-05-02: Mid-Morning Market Update: Markets Mostly Flat; Pfizer Profit Beats Views

Financial news for SNSS dated on 2017-05-02: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for SNSS dated on 2017-05-01: Adam F Tweets: I've spoken to few buysiders own \$SNSS for SNS-062, early, different BTK inhibitor. "Thrilled" to see vosa off the books, one just told me.

Financial news for SNSS dated on 2017-05-01: Sunesis Pharma Reports Withdrawal of European MAA for Vosaroxin as Treatment for Relapsed/Refractory AML

Financial news for SNSS dated on 2017-04-12: 8-K from Sunesis Pharma Shows CFO Eric Bjerkholt to Resign; Co. to Initiate Search for Replacement Candidate

Financial news for SNSS dated on 2017-03-22: Sunesis Pharma Reports Submission of Responses to EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin

Financial news for SNSS dated on 2017-01-23: Sunesis Pharmaceuticals Reports FDA Review Of INDa For SNS-062 Complete; Says Vosaroxin Outstanding Issues Received And Will Go Before Scientific Advisory Group In April Prior To CHMP Opinion

Financial news for SNSS dated on 2016-11-03: Sunesis Pharmaceuticals Reports Q3 EPS \$(0.62) vs. Est. \$(0.71), Rev. \$610K vs. Est. \$600K

Financial news for SNSS dated on 2016-10-19: Sunesis Announces Pricing of \$25 Million Offering of Securities, 4.93M Shares At \$3.85/Share

Financial news for SNSS dated on 2016-10-18: Sunesis Reports Offering of Common Stock, Series C Convertible Preferred Shares, No Amount Disclosed

Financial news for SNSS dated on 2016-10-13: UPDATE: Sunesis Says Expects to Receive EMA Day 180 List of Outstanding Issues Before Year End

Financial news for SNSS dated on 2016-10-13: Sunesis Reports Submission of Response to EMA Day 120 List of Questions for MAA for Vosaroxin

Financial news for SNSS dated on 2016-09-12: Sunesis Phase 1A Study of SNS-062 Showed

Favorable Safety, Pharmacokinetic and Pharmacodynamic Results

Financial news for SNSS dated on 2016-07-29: Sunesis Upgraded To Outperform At Wells Fargo

Financial news for SNSS dated on 2016-07-29: Sunesis Pharmaceuticals Reports Q2 EPS \$(0.12) vs. Est. \$(0.10), Rev. \$610K vs. Est. \$1M

Financial news for SNSS dated on 2016-05-19: Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the EHA

Financial news for SNSS dated on 2016-05-05: Sunesis Pharmaceuticals Reports Q1 EPS \$(0.12) vs. Est. \$(0.12)

Financial news for SNSS dated on 2016-03-24: Sunesis Pharma Reports First Patient Treated in Phase 2 VITAL Study of Vosaroxin in Combo with Infusional Cytarabine in Patients with Previously Untreated AML

Financial news for SNSS dated on 2016-03-23: Sunesis Pharma Reports First Dosing in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

Financial news for SNSS dated on 2016-03-23: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

Financial news for SNSS dated on 2016-03-10: Sunesis Pharmaceuticals Reports Q4 EPS \$(0.15) vs. Est. \$(0.14)

Financial news for SNSS dated on 2016-01-07: Growth Equity Opportunities Fund Reports 9% Stake In Sunesis Pharmaceuticals 13D Filing

Financial news for SNSS dated on 2016-01-05: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals to Speculative Buy

Financial news for SNSS dated on 2016-01-04: Sunesis Pharma Reports EMA Validation of MAA for Vosaroxin in AML

Financial news for SNSS dated on 2015-12-22: Amended 13D Filing from Bay City Capital on Sunesis Pharma Shows 8.52% Stake

Financial news for SNSS dated on 2015-12-22: Director Misfeldt Buys 1,750,000 Shares of Sunesis Pharmaceuticals @\$0.84/Share -Form 4

Financial news for SNSS dated on 2015-12-16: Sunesis Prices 9.561M Shares At \$0.84/Share

Financial news for SNSS dated on 2015-12-08: Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe

Financial news for SNSS dated on 2015-12-07: Sunesis Pharmaceuticals Announces Positive Results Regarding ongoing Phase 1b/2 University of Texas MD Anderson cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients

Financial news for SNSS dated on 2015-12-06: Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015

Financial news for SNSS dated on 2015-12-03: Sunesis Reports Partnership with Clinigen Group Related to Initiation of Compassionate Use Program for Patients with Relapsed, Refractory AML

Financial news for SNSS dated on 2015-12-01: Sunesis Pharma Initiates IU Pilot Study Of Vosaroxin, Cytarabine Treatment In ~17 Patients 60 Years or Older With Untreated AML

Financial news for SNSS dated on 2015-11-30: Sunesis Pharma Announces European Patent For Vosaroxin Combination Use

Financial news for SNSS dated on 2015-11-05: Sunesis Pharmaceuticals Reports Q3 Loss \$0.09 Vs Est Loss \$0.15

Financial news for SNSS dated on 2015-11-04: Sunesis Pharma Reports Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at CFS

Financial news for SNSS dated on 2015-10-07: Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End

Financial news for SNSS dated on 2015-07-29: Sunesis Pharmaceuticals CEO Swisher Jr Buys 25,000 Shares @\$1.02/Share -Form 4

Financial news for SNSS dated on 2015-07-26: Biotech Stocks Falling Broadly, Here's Why And How Much

Financial news for SNSS dated on 2015-07-24: Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora

Financial news for SNSS dated on 2015-07-24: Worst Performing Industries For July 24, 2015

Financial news for SNSS dated on 2015-07-24: Morning Market Losers

Financial news for SNSS dated on 2015-07-24: Benzinga's Top Downgrades

Financial news for SNSS dated on 2015-07-24: Roth's Pantginis Downgrades Sunesis, Price Target Smashed To \$1.00 On 'Many Outstanding Questions'

Financial news for SNSS dated on 2015-07-24: Cowen & Company Downgrades Sunesis Pharmaceuticals to Market Perform

Financial news for SNSS dated on 2015-07-23: Sunesis Pharma Shares Plunge 60%+ Following Release Suggesting Co. Has Been Informed FDA Will Not Support Recent Vosaroxin Filing

Financial news for SNSS dated on 2015-07-23: Sunesis Pharmaceuticals Reports Regulatory Update

Financial news for SNSS dated on 2015-07-01: Option Alert: Sunesis Aug \$4 Call Sweep; 2000 Contracts at Ask @\$0.15

Financial news for SNSS dated on 2015-06-30: Option Alert: Sunesis Aug \$4 Call Sweep; 1575 Contracts above Ask @\$0.34

Financial news for SNSS dated on 2015-06-30: Option Alert: Sunesis Pharmaceuticals Aug \$4 Call; 2141 Contracts Traded vs 3 OI; Now \$2.96

Financial news for SNSS dated on 2015-06-15: Roth Capital's Pantginis Says 'Cautious Optimism Grows' on Sunesis Pharma, Warns 'AML Still Dire Need,' Raises Target from \$4 to \$5.50

Financial news for SNSS dated on 2015-06-15: Roth Capital Maintains Buy on Sunesis Pharmaceuticals, Raises PT to \$5.50

Financial news for SNSS dated on 2015-06-12: Morning Market Gainers

Financial news for SNSS dated on 2015-06-12: Sunesis Pharma Offers New Data from VALOR Trial for Vosaroxin in Older Patients with Acute Myeloid Leukemia

Financial news for SNSS dated on 2015-05-31: Sunesis Pharmaceuticals Presents VALOR Trial Subgroup Analysis at ASCO

Financial news for SNSS dated on 2015-05-21: Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

Financial news for SNSS dated on 2015-03-12: Sunesis Pharma Q4 EPS -\$0.02 vs -\$0.20 est

Financial news for SNSS dated on 2015-01-12: Option Alert: Sunesis Pharmaceuticals Feb \$3 Call; 6,900 Contract Trade at Bid @\$0.30; Currently \$2.79

Financial news for SNSS dated on 2015-01-08: Option Alert: Sunesis Pharmaceuticals Feb \$3 Call, 1,037 Contract Trade at Ask @\$0.45; Currently \$2.69

Financial news for SNSS dated on 2015-01-05: BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will Be Breakeven By 2017'

Financial news for SNSS dated on 2015-01-05: BTIG Research Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces \$5.50 PT

Financial news for SNSS dated on 2014-12-15: Roth Capital Upgrades Sunesis Pharmaceuticals, Inc. to Buy, Raises PT to \$4.30

Financial news for SNSS dated on 2014-12-10: Sunesis Pharmaceuticals Shares Rise 13% Premarket Following Cantor Fitzgerald Upgrade to Buy

Financial news for SNSS dated on 2014-12-10: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals, Inc. to Buy

Financial news for SNSS dated on 2014-12-08: Sunesis Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS at ASH Annual Meeting

Financial news for SNSS dated on 2014-12-08: Morning Market Losers

Financial news for SNSS dated on 2014-12-07: Sunesis Pharmaceuticals to Presentat Results from Phase 3 VALOR Trial at ASH Annual Meeting

Financial news for SNSS dated on 2014-11-25: Option Alert: Sunesis Pharmaceuticals Dec \$2 Call; 1,000 Contract Trade at Ask @\$.50; Currently \$2.22

Financial news for SNSS dated on 2014-11-24: UPDATE: Sunesis Reports Schedule C Had Most Favorably Safety/Efficacy Balance

Financial news for SNSS dated on 2014-11-24: Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology

Financial news for SNSS dated on 2014-11-19: Sunesis Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica

Financial news for SNSS dated on 2014-11-17: Option Alert: Sunesis Dec \$2.5 Call; 2,027 Contract Trade at Ask @\$.30; Currently \$2.31

Financial news for SNSS dated on 2014-11-17: Sunesis Pharmaceuticals Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At ASH Annual Meeting

Financial news for SNSS dated on 2014-11-10: Sunesis Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.25) vs \$(0.17) Est

Financial news for SNSS dated on 2014-11-10: Earnings Scheduled For November 10, 2014

Financial news for SNSS dated on 2014-10-07: Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth

Financial news for SNSS dated on 2014-10-07: Roth Capital Downgrades Sunesis Pharmaceuticals, Inc. to Buy, Lowers PT to \$15.00

Financial news for SNSS dated on 2014-10-06: RBC Capital Downgrades Sunesis Pharmaceuticals, Inc. to Sector Perform, Lowers PT to \$3.00

Financial news for SNSS dated on 2014-10-06: U.S. Stocks Turn Red; CareFusion Shares Surge On Announcement Of Acquisition By Becton, Dickinson

Financial news for SNSS dated on 2014-10-06: Wedbush Maintains Neutral on Sunesis Pharmaceuticals, Inc., Lowers PT to \$2.00

Financial news for SNSS dated on 2014-10-06: Markets Open Higher; Hewlett-Packard Plans To Split Into Two Companies

Financial news for SNSS dated on 2014-10-06: Stocks Hitting 52-Week Lows

Financial news for SNSS dated on 2014-10-06: Morning Market Losers

Financial news for SNSS dated on 2014-10-06: Benzinga's Top #PreMarket Losers

Financial news for SNSS dated on 2014-10-06: Sunesis Shares Fall 64% Premarket as Pivotal Phase 3 VALOR Trial of Acute Myeloid Leukemia Treatment does Not Meet Primary Endpoint

Financial news for SNSS dated on 2014-10-06: Sunesis Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine Does Not Reach Primary Endpoint

Financial news for SNSS dated on 2014-09-02: Shares of Sunesis Pharmaceuticals Move Lower; May be Attributed to Adam F/Street.com Article

Financial news for SNSS dated on 2014-08-29: Option Alert: Sunesis Pharma Oct \$14 Call; 1,022 Contracts Traded vs 529 OI; Currently \$7.45

Financial news for SNSS dated on 2014-08-29: Morning Market Losers

Financial news for SNSS dated on 2014-08-29: Benzinga's Top Downgrades

Financial news for SNSS dated on 2014-08-29: Wedbush Downgrades Sunesis Pharmaceuticals To Neutral, Shares Drop

Financial news for SNSS dated on 2014-08-29: Wedbush Downgrades Sunesis Pharmaceuticals, Inc. to Neutral

Financial news for SNSS dated on 2014-08-27: UBS Says Sunesis Leukemia Pivotal Trial Success 'Likely'

Financial news for SNSS dated on 2014-08-27: Shares of Sunesis Pharma Spiked Over \$8 Level During Last Hour, Traders Attributing Move to CNBC Mention of Comments from UBS Analyst in Early-Morning Research Note

Financial news for SNSS dated on 2014-08-05: Sunesis Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.20) vs \$(0.17) Est; Revenue of \$1.99M vs \$1.21M Est

Financial news for SNSS dated on 2014-07-09: Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo For AML

Financial news for SNSS dated on 2014-06-17: Events Scheduled for Week of Jun. 16th to Jun. 20th

Financial news for SNSS dated on 2014-06-11: UBS Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Buy, Announces \$14.00 PT

Financial news for SNSS dated on 2014-06-02: Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting

Financial news for SNSS dated on 2014-04-22: Sunesis Announces Data of Ongoing Vosaroxin Study at ASCO

Financial news for SNSS dated on 2014-04-10: Mid-Morning Market Update: Markets Drop; Family Dollar Plans To Close 370 Stores

Financial news for SNSS dated on 2014-04-08: Sunesis Reports Presentation of Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML, High-Risk MDS

Financial news for SNSS dated on 2014-04-02: Sunesis MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014

Financial news for SNSS dated on 2014-03-06: Sunesis Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.15) vs \$(0.20) Est

Financial news for SNSS dated on 2014-03-05: Leerink Swann Boosts Target on Sunesis Pharma from \$14 to \$17, Maintains Outperform

Financial news for SNSS dated on 2014-02-27: Sunesis Prices \$43M Offering of Stocks, Warrants, Expecting Total Gross Proceeds \$138.3M

Financial news for SNSS dated on 2014-02-26: Sunesis Announces Proposed Public Offering

Financial news for SNSS dated on 2014-02-10: Sunesis Names Joseph I. DePinto Chief Commercial Officer

Financial news for SNSS dated on 2014-02-07: Hearing Cowen Positive on Sunesis Pharmaceuticals

Financial news for SNSS dated on 2014-01-09: Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs

Financial news for SNSS dated on 2013-12-10: Sunesis Pharmaceuticals Initiates Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS

Financial news for SNSS dated on 2013-11-12: Sunesis Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.16) vs \$(0.20) Est; Revenue of \$1.99M vs \$1.44M Est

Financial news for SNSS dated on 2013-10-28: Sunesis Pharmaceuticals Announces Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome

Financial news for SNSS dated on 2013-07-31: Benzinga's Top Initiations

Financial news for SNSS dated on 2013-07-31: Credit Suisse Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Buy, Announces \$25.00 PT

Financial news for SNSS dated on 2013-07-29: Sunesis Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.18) vs \$(0.21) Est; Revenue of \$1.99M vs \$1.22M Est

Financial news for SNSS dated on 2013-06-13: Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct

Financial news for SNSS dated on 2013-05-09: Sunesis Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.23) vs \$(0.20) Est

Financial news for SNSS dated on 2013-04-10: Sunesis Pharma Files \$150M Mixed Securities Shelf

Financial news for SNSS dated on 2013-03-13: Sunesis Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.20) vs \$(0.19) Est; Revenue of \$1.99M vs \$320.0K Est

Financial news for SNSS dated on 2013-03-13: Earnings Scheduled For March 13, 2013

Financial news for SNSS dated on 2013-02-07: Sunesis Pharmaceuticals Spikes Lower

Financial news for SNSS dated on 2013-01-15: UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data

Financial news for SNSS dated on 2013-01-15: Credit Suisse Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Outperform, Announces \$7.00 PT

Financial news for SNSS dated on 2012-12-20: From Earlier: Wells Fargo Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Outperform

Financial news for SNSS dated on 2012-10-05: Wedbush Securities Maintains Sunesis Pharmaceuticals at Outperform, Raises PT from \$7 to \$10

Financial news for SNSS dated on 2012-10-02: Sunesis Pharmaceuticals Spokesperson Says No News to Account for Spikedown

Financial news for SNSS dated on 2012-10-02: Sunesis Pharmaceuticals Spikes Lower

Financial news for SNSS dated on 2012-09-20: Sunesis Pharmaceuticals Announces Closing of \$40 Million in Previously Announced Royalty and Debt Financings

Financial news for SNSS dated on 2012-09-11: Wedbush Securities Maintains Sunesis Pharmaceuticals at Outperform, Raises PT from \$4 to \$7

Financial news for SNSS dated on 2012-09-11: Stocks Hitting 52-Week Highs

Financial news for SNSS dated on 2012-09-11: Morning Market Movers

Financial news for SNSS dated on 2012-09-11: UPDATE: Sunesis Pharmaceuticals Rises 46% Pre-Market on Increase in Patient Sample Size in Acute Myeloid Leukemia Trial

Financial news for SNSS dated on 2012-09-11: From Earlier: Sunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase 3 VALOR Trial in AML

Financial news for SNSS dated on 2012-08-09: Sunesis Pharmaceuticals Reports Q2 EPS \$-0.20 vs \$-0.20 Est

Financial news for SNSS dated on 2012-06-15: Cantor Fitzgerald Reiterates Buy Rating, \$6 PT for Sunesis Pharmaceuticals

Financial news for SNSS dated on 2012-04-13: Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals with Buy Rating, \$6 PT

Financial news for SNSS dated on 2012-04-13: Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces PT of \$6

Financial news for SNSS dated on 2012-04-01: Benzinga's Microcap Movers for Friday March 30, 2012

Financial news for SNSS dated on 2012-03-29: Sunesis and Royalty Pharma Announce \$25M Vosaroxin Royalty Agreement

Financial news for SNSS dated on 2012-03-06: Canaccord Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces PT of \$4

Financial news for SNSS dated on 2012-03-05: Benzinga's Microcap Movers for Monday March 5, 2012

Financial news for SNSS dated on 2012-02-14: A Peek Into The Market Before The Trading Starts

Financial news for SNSS dated on 2012-02-14: Sunesis Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Covering Vosaroxin Compositions

Financial news for SNSS dated on 2012-01-26: Small Biotechnology Stocks Roar, Profit Now

Financial news for SNSS dated on 2011-12-12: Sunesis Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients

Financial news for SNSS dated on 2011-10-19: Sunesis Secures \$25 Million Tranched Loan Facility

Financial news for SNSS dated on 2011-10-07: Hearing Wedbush Initiates Sunesis Pharmaceuticals with \$4 PT

Financial news for SNSS dated on 2011-09-29: MLV Initiates Coverage of Sunesis Pharmaceuticals with a Buy Rating

Financial news for SNSS dated on 2011-09-29: MLV Initiates Sunesis Pharmaceuticals with Buy; \$3.50 PT

Financial news for SNSS dated on 2011-09-26: Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors

Financial news for SNSS dated on 2011-09-26: Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors

Financial news for SNSS dated on 2011-08-08: NASDAQ Stocks Hitting 52-Week Lows

Financial news for SNSS dated on 2011-08-03: Sunesis Pharmaceuticals Issued U.S. Patent Covering Vosaroxin Use to Treat Leukemia

Financial news for SNSS dated on 2011-07-20: Sunesis Announces Publication of Phase 1b Data of Vosaroxin in Relapsed or Refractory Acute Leukemia

Financial news for SNSS dated on 2011-06-07: Top Percentage Gainers and Losers as of 2pm 06/07/11

Financial news for SNSS dated on 2011-06-07: Top Percentage Gainers and Losers as of 12pm 06/07/11

Financial news for SNSS dated on 2011-06-06: Sunesis Announces Presentation of Adaptive Study Design for Vosaroxin Phase 3 VALOR Trial in AML at ASCO 2011 Annual Meeting

Financial news for SNSS dated on 2011-05-12: Top Percentage Gainers and Losers as of 2pm 5/12/11 (DSCO, OXGN, QCOR, QTWW, SNSS, RPTP, VICL, ORBK, PNSN, SPMD, CLWR, DEXO, CCIH, TNGN, NQ, SYMX, BAC, INTC)

Financial news for SNSS dated on 2011-05-05: Sunesis Announces Publication of Nonclinical Data Demonstrating Activity of Vosaroxin Alone and in Combination With Cytarabine in Patients' Acute Myeloid Leukemia Blasts (SNSS)

Financial news for SNSS dated on 2011-04-11: Top Percentage Gainers and Losers as of 2 p.m. 4/11/2011(TSTY, FLO, GLBC, LVLT, AMMD, ENDP, EFII, IDIX, BAC, SNSS, AFFX, MCP, CYH, QUIK, THC, TDSC, WPRT, SCEI, IRE)

Financial news for SNSS dated on 2011-04-05: Morning Roundup: Top-5 and Bottom-5 Percentage Gainers (CBST, QCOR, SNSS, PPHM, EXPE, LEDS, MERU, PSEC, CREE, AIXG)

Financial news for SNSS dated on 2011-03-29: Sunesis Pharmaceuticals Reports Q4 Loss of \$0.23 per share

Financial news for SNSS dated on 2011-03-29: Sunesis Pharmaceuticals Reports Q4 EPS of \$(0.23) vs. \$(0.10)

Financial news for SNSS dated on 2011-02-14: Sunesis Announces 1-for-6 Reverse Stock Split

Financial news for SNSS dated on 2010-12-20: RBC Capital Ups SNSS To Outperform

Financial news for SNSS dated on 2010-10-20: Adam Feuerstein Thinks Merger May Be In Works In Biotech (CTIC, SNSS)

Financial news for SNSS dated on 2010-01-14: Benzinga's Top Pre-Market Gainers (OSTE, FMBI, SNSS, HNSN, CPBY, ETRM)

Financial news for SNSS dated on 2010-01-14: Benzinga's News Roundup (SEED, WSM, FPL, SNSS, ETRM, AIR, RXII)

Financial news for SNSS dated on 2009-12-16: Benzinga's Biggest Losers (HLCS, CYCC, SNSS, AMED, APKT)

Financial news for SNSS dated on 2009-12-11: Benzinga's Top Gainers (SNSS, CBK, AA, NCR, ERJ)